N30 raises $30M for cystic fibrosis drug; Ironwood lands $15M milestone from Astellas; Ikaria partners on China;

@FierceBiotech: Success or failure, feds want trial results posted online. Article | Follow @FierceBiotech

@JohnCFierce: U.K. heavyweight Woodford gambles $25M on controversial brain cancer vaccine. Report | Follow @JohnCFierce

@DamianFierce: Important M&A code name update from @BloombergNews: $AGN was "Avocado" to $ACT and "Apollo" to $VRX. Article | Follow @DamianFierce

> Boulder, CO-based N30 Pharmaceuticals has raised $30 million in mezzanine financing for their work on cystic fibrosis. The biotech is working on a clinical program for N91115, a novel inhibitor of S-nitrosoglutathione reductase. New investors include Wellington Management, RA Capital Management, LLC, Jennison Associates LLC (on behalf of certain clients), Rock Springs Capital Management LP, and Sabby Management, LLC, who joined existing investor, Deerfield Management Company. Release

> Ironwood ($IRWD) picked up a $15 million milestone from Astellas, its partner in Japan on linaclotide. The payment was triggered by Astellas' recruitment of the first patient for a Phase III study. Release

> Hong Kong-based Lee's Pharmaceutical has struck a deal to partner with Ikaria on Inomax for the Chinese market. The therapy is designed to treat hypoxic respiratory failure associated with pulmonary hypertension in term and near-term infants greater than 34 weeks gestational age. Release

Medical Device News

@FierceMedDev: From FierceDrugDelivery: Medical marijuana company licenses RapidMist device for buccal delivery. Story | Follow @FierceMedDev

@StacyALawrence: Second Sight IPO pops 122% in first day. That's 8th largest IPO pop this year in any sector. Updated story | Follow @StacyALawrence

@VarunSaxena2: Smith & Nephew closes U.S. facility, sells another in U.K. with 100+ to be laid off. More | Follow @VarunSaxena2

@EmilyWFierce: More on how the Cystic Fibrosis Foundation's deal with Royalty Pharma could affect R&D and patients. NYT story | Follow @EmilyWFierce

> Smith & Nephew closes a facility in the U.S., sells another in the UK, 100+ to be laid off. More

> New paradigms in diagnostics: graphene and a single drop of blood. Editor's Corner

> Molecular nuclear imaging startup to use $100M IPO to advance Phase III therapeutic. Article

Pharma News

@FiercePharma: ICYMI: This week's full issue of FiercePharmaMarketing. Subscribe here. | Follow @FiercePharma

@CarlyHFierce: U.K. health secretary: Novartis holding government to 'ransom' with Bexsero pricing. FierceVaccines article | Follow @CarlyHFierce

> Court shoots down Ranbaxy's bid to block rival Nexium and Valcyte generics. More

> So long, patent cliff. Hello, hep C and cancer. Welcome to $1.3T in global drug spending. Article

Vaccines News

> PATH chooses Mymetics for work on transmission-blocking malaria vax. Item

> U.K. health secretary: Novartis holding government to 'ransom' with Bexsero pricing. More

> Pfizer's MenB reach--and lead on Novartis--limited without ACIP nod. Report

> NewLink Ebola vaccine trial to start in Canada. Article

> Celldex glioblastoma vaccine extends survival in Phase II. Story

Pharma Manufacturing News

> Ranbaxy can't stop the FDA from yanking drug approvals over plant problems. Item

> Amgen opens $200M continuous purification plant in Singapore. Story

> Doc coughs up $2M for using unapproved Avastin on his cancer patients. Report

> Interpol: Organized crime, aware of weak points, targets counterfeit drugs. Story

> U.K. generics maker to build $31M plant in Alabama. Article

Free Webinar

From Patient Adherence to Manufacturing Ease - Why Softgels Make Sense for Rx

Join Thermo Fisher Scientific’s upcoming webinar to learn why softgels offer numerous benefits for Rx drug development, including enhanced bioavailability, patient compliance and easy scale-up. Register Today.

Suggested Articles

Polyphor is developing an inhaled version of murepavadin, which targets Pseudomonas aeruginosa infections, but is currently given intravenously.

Japanese pharma Astellas is looking to offload a series of unwanted research projects ahead of Thanksgiving; if you want one, it’s made it very easy.

A re-engineered adenovirus prolonged survival in mouse models of metastatic lung cancer and cleared tumors in about 35% of the animals.